[Retrospective study of acute myelogenous leukemia in elderly patients: treatment and outcome of 83 consecutive patients].
We retrospectively analyzed treatments and outcomes for 83 acute myelogenous leukemia (AML) patients aged 60 years or more (median age 71) admitted to our hospital between August 1984 and January 1998. Complete remission was achieved in 36% of 78 patients who received anti-leukemic therapy, and median overall survival was 227 days. In addition to abnormal karyotypes involving chromosome 5 or 7, administration of less than 120 mg/m2/course of daunorubicin (DNR) during the initial treatment phase was an unfavorable prognostic factor for both CR and survival. Only 41% of all patients received 120 mg/m2/course of DNR or more, and had a significantly higher CR rate (56%) and longer survival, with a median of 389 days. It was suggested that intensive chemotherapy was effective for selected elderly AML patients who were relatively younger and had good performance status, although the number of such patients was limited in our study.
Ino
T
T
Department of Medicine, Fujita Health University School of Medicine.
Tsuzuki
M
M
Hasegawa
A
A
Miyazaki
H
H
Kojima
H
H
Maruyama
F
F
Okamoto
M
M
Matsui
T
T
Ezaki
K
K
Hirano
M
M
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002895:Chromosomes, Human, Pair 5; D002897:Chromosomes, Human, Pair 7; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017353:Gene Deletion; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
D003561:Cytarabine; D014212:Tretinoin; D008942:Mitoxantrone; D003630:Daunorubicin